Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?
Debate Over Need For, Impact Of Plan
Executive Summary
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.
You may also be interested in...
As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
Pressure Mounts On EU To Follow US In Backing COVID-19 Vaccine IP Waiver
The pharmaceutical industry in Europe has attacked the US decision to come out in support of a relaxation of IP rights that is designed to boost global production of COVID-19 vaccines. But the move by the Biden administration could well cause other countries to rethink their opposition to the move.